NEW YORK (GenomeWeb News) – Danaher today said that revenues in the third quarter were down a fraction of 1 percent year over year as the company missed the consensus Wall Street estimate on the top and bottom line.

For the three months ended Sept. 28, revenues totaled $4.42 billion, compared to $4.45 billion a year ago, and short of the average analyst estimate of $4.51 billion.

Danaher said that core revenues grew 1 percent year over year while acquisitions added 1.5 percent to growth. The impact of currency translations shrank revenues by 3 percent, however.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.